Track market-moving stories before they get noisy

President Trump's agreement with Japan unlocks up to $21 billion investment to expand foundational semiconductor production, support American jobs and strengthen domestic supply chains

 | Source:

GlobalFoundries Inc.

MALTA, N.Y., Oct. 14, 2026 (GLOBE NEWSWIRE) -- GlobalFoundries (Nasdaq: GFS) (GF) today announced it has been selected as the technology provider and operator for two new semiconductor manufacturing facilities (“fabs”) at its Malta, New York, site under a U.S.-Japan initiative providing up to $21 billion in funding. Enabled by President Donald J. Trump's trade and investment agreement with Japan, the initiative will accelerate trusted semiconductor manufacturing in the United States, strengthen critical supply chains and support growing demand across automotive, industrial and connected infrastructure markets.

Japan will provide the investment, while GF will contribute its differentiated technologies, manufacturing expertise and proven operational capabilities as technology provider and operator.

An initial investment of approximately $10 billion will accelerate construction of a new 300mm semiconductor fab, which is expected to come online in 2029. An additional investment of approximately $10 billion would fund a second fab. Together, the two fabs will add significant new U.S. manufacturing capacity and reinforce GF's ability to support customers worldwide.

“This is a bold new initiative for semiconductor manufacturing, bringing together the United States and Japan with GF’s differentiated technology and decades of manufacturing expertise to accelerate trusted capacity in New York,” said Tim Breen, CEO of GlobalFoundries. “GF was selected because fabs of this scale require more than capital. They require differentiated technology, operational excellence and a proven ability to execute. That combination is what positions GF to make this first-of-its-kind initiative a success.”

The first fab is expected to add approximately 900,000 300mm wafers of annual U.S. manufacturing capacity when fully operational. A second fab would add approximately the same amount. The project is expected to create about 27,000 construction and ecosystem jobs and more than 1,000 high-skilled manufacturing jobs in New York's Capital Region.

“President Trump’s historic U.S.-Japan Trade Deal is delivering another massive manufacturing investment into America,” said Secretary of Commerce Howard Lutnick. “With Japan’s investment funding and GlobalFoundries’ partnership, two large semiconductor chip manufacturing facilities will be built in the U.S., creating thousands of high-paying jobs for American workers. This is how the President’s trade agreements result in transformational American industrial assets that strengthen our national and economic security.”

GF has also agreed with the U.S. Department of Commerce to amend its existing CHIPS and Science Act award to reallocate $955 million and accelerate the company’s investments in silicon photonics, silicon-germanium (SiGe) and advanced packaging at its facilities in Malta, New York, and Burlington, Vermont. These investments will expand domestic manufacturing capacity for technologies increasingly critical to communications infrastructure and data centers.

In a separate agreement, the U.S. Department of Commerce will receive equity in GF of approximately four percent, further enabling the American public to share in GF’s growth.

Breaking ground in New York

GF expects to break ground on the first fab at its Malta site later this year. The site is permitted and shovel-ready, using existing Malta infrastructure to speed construction. Details of a groundbreaking event will be announced separately.

Expanding American manufacturing

New York State continues to support the Capital Region’s semiconductor ecosystem through its Green CHIPS program.

"GlobalFoundries’ expansion in Malta is a tremendous vote of confidence in New York's world-class workforce, innovation ecosystem and the Capital Region's growing role as a global hub for semiconductor manufacturing and innovation," said New York Governor Kathy Hochul. "We also look forward to working with the Government of Japan and partnering with their world-leading semiconductor supply chain ecosystem in the years to come. This investment will create thousands of construction jobs, support more than 1,000 highly skilled manufacturing jobs and reinforce New York's position as a global hub for the semiconductor industry."

“Since 2009, the people of this site have built one of the nation’s most advanced semiconductor manufacturing operations,” said Grant McEwan, general manager of Fab 8 at GlobalFoundries. “These two great countries entrusting GF to operate two new fabs is a powerful vote of confidence in our workforce, our technology and New York’s Capital Region. With the potential to create thousands of new jobs, we are working with education and workforce partners to build the next generation of semiconductor talent. This is a milestone for our employees, our region and the future of advanced manufacturing in New York.”

Built for customers and partners

The new capacity builds on long-standing customer relationships across the United States and Japan.

"We are planning around GF's new capacity in New York as an extension of Renesas’ own production footprint, trusted U.S.-based manufacturing backed by a strong U.S.-Japan partnership," said Hidetoshi Shibata, CEO of Renesas. "This expanded collaboration further strengthens the stable, long-term supply of semiconductors with the differentiated technologies, quality and reliability our products require. These capabilities are essential as we deliver advanced solutions, with demand for electrification, connectivity, AI and data center applications accelerating worldwide."

“Resilient semiconductor manufacturing depends on a trusted ecosystem of equipment and technology partners," said Tony Kawai, president & CEO of Tokyo Electron. “Tokyo Electron has supported GlobalFoundries’ manufacturing operations across its global sites for many years, and we are pleased to contribute to expanding advanced semiconductor production capacity in the United States. We also recognize the importance of developing talent and fostering strong local communities to sustain long-term industry growth. This reflects the strong and deeply integrated U.S.-Japan collaboration that underpins the global semiconductor industry.”

“We’ve partnered with GlobalFoundries to produce essential chips for Apple products right here in the United States, as part of our $600 billion commitment to American investment,” said Sabih Khan, Apple’s COO. “As an inaugural member of Apple’s American Manufacturing Program, GlobalFoundries shares our belief in the power of American innovation and ingenuity. This new investment will help accelerate the advanced semiconductor manufacturing ecosystem in the United States.”

“The new fabs in Malta strengthen the U.S. semiconductor ecosystem and give Cirrus Logic access to important domestic manufacturing capability for next-generation mixed-signal products,” said John Forsyth, Cirrus Logic president and CEO. “Building on our long-standing relationship with GF, this new capacity supports the secure, resilient supply chains our customers rely on and broadens the foundation for future innovation.”

“GM is making strategic investments in autonomy and centralized computing to power the next generation of software-defined vehicles and deliver customer-focused technologies at scale, including widespread deployment of AI across our vehicles and breakthrough capabilities like next-generation Super Cruise. This requires significant processing power and a strong, resilient semiconductor supply chain,” said Mark Reuss, president, GM. “GM and GF established the first direct automaker-to-foundry supply agreement, and expanding domestically owned and operated fab capacity in upstate New York marks a decisive step forward for American manufacturing.”

Investor webinar

GF will host a webcast for investors and analysts on October 14 at 1 p.m. EDT to discuss the announcement. A live webcast and replay will be available at investors.gf.com.

About GF

GlobalFoundries (GF) is a leading manufacturer of essential semiconductors, enabling AI at scale from the cloud to the physical world. Through deep partnerships with customers, GF delivers differentiated, power-efficient and high-performance solutions for automotive, aerospace and defense, data center, smart mobile devices, internet of things and other high-growth markets. With global manufacturing operations across the U.S., Europe and Asia, GF is a trusted and holistic technology partner for customers around the world. GF’s talented, global team remains focused every day on security, longevity and sustainability. For more information, visit www.gf.com.

Forward looking information

This press release includes “forward-looking statements” under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995 and include but are not limited to, statements regarding accelerated manufacturing capacity, anticipated funding and investment, our financial outlook, future guidance, product development, business strategy and plans, and market trends, opportunities and positioning. These statements are based on current expectations, assumptions, estimates, forecasts, projections and limited information available at the time they are made. Words such as “expect,” “anticipate,” “should,” “estimate,” “may,” “will,” “could,” “intend,” "outlook," and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to a broad variety of risks and uncertainties, both known and unknown. Any inaccuracy in our assumptions and estimates could affect the realization of expectations or forecasts. For example, our business could be impacted by geopolitical conditions including trade tensions, tariffs, and political or policy developments; the market for our products may not develop as expected; our operating results and cash flows may fluctuate more than expected; a network or data security incident may result in system disruptions, loss of data or damage our reputation; global economic conditions could deteriorate; the expected benefits of our announced partnerships may fail to materialize; and we may fail to achieve the anticipated results or benefits from government grants and our expected results and planned or further expansions and operations may not proceed as planned if expected funding is delayed or withheld for any reason. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business. Moreover, new risks may emerge from time to time.

Although we believe that the expectations reflected in our statements are reasonable, we cannot guarantee that the anticipated results or achievements will occur. Moreover, neither we, nor any other person, assumes responsibility for the accuracy and completeness of these statements. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact or guarantees of future events. Except to the extent required by federal securities laws, we undertake no obligation to update any forward-looking statements after the date hereof, or to conform these statements to actual results. Please refer to the risk factors and cautionary statements in our 2025 Annual Report on Form 20-F, current reports on Form 6-K and other reports filed with the Securities and Exchange Commission (SEC), copies of which are available at investors.gf.com, or from the SEC website, www.sec.gov.

Media contacts

Erica McGill
GlobalFoundries
[email protected]

Kenneth Craig
GlobalFoundries
[email protected]

Kinder Morgan stock has rebounded this month, moving from a low of $29.48 on October 1 to the current $33.43. It has jumped to its highest level since May 20th, with focus now shifting to its upcoming earnings report. It is up by over 30% from its lowest level this year.

Kinder Morgan is a leading energy infrastructure company. It does not produce oil and gas. Instead, it uses its extensive pipeline network to transport energy to its clients. Most of its business is in natural gas, which is seeing strong growth. The US-Iran war has boosted demand for US gas from Asian and European countries, while the ongoing data center boom has driven a surge in domestic gas demand.

Kinder Morgan’s business has done well this year, with its revenue and profits soaring. The most recent results showed that revenue jumped to $4.47 billion in the June quarter from $4.04 billion in the same period last year. As a result, its net income rose to $894 million from the previous $742 million.

For the first half of the year, Kinder Morgan’s revenue and profits rose to $9.3 billion and $1.8 billion, respectively. As a result, the board of directors decided to boost its dividends to its shareholders. 

Focus today will be on its earnings report, which will provide more information about the impact of a recent outage to Mexico. Yahoo Finance data shows that analysts expect the upcoming report to show that revenue rose 5.72% to $4.38 billion, with its earnings per share rising to 33 cents. 

The options market expects a muted reaction to earnings. This is in line with how it has reacted to its earnings in the past. For example, its stock dropped by less than 1% after releasing its earnings report. It also dropped by less than 2% after its previous earnings report in April.

The company has an implied volatility of 24%, slightly higher than the historical average of 19%. It has a put-to-call ratio of 0.15, suggesting bullish positioning, with most of the calls sitting at $34, slightly higher than the current $33.

Analysts are modestly bullish on KMI stock. Royal Bank of Canada has a target of $36, while Melius Research targets $38. JPMorgan and Argus have a target of $36 and $38, respectively.

KMI stock chart | Source: TradingView

The daily chart shows that Kinder Morgan shares have bounced back in the past few days, moving from a low of $29.48 on October 1 to the current $33.43. It has crossed the important resistance level of $33, its highest level in June, July, and August this year.

The stock has jumped above the 100-day moving average and the ultimate resistance of the Murrey Math Lines tool. Top oscillators like the Relative Strength Index (RSI) and the MACD have continued rising.

Therefore, the stock will likely have a bullish breakout, potentially to the crucial resistance level of $34.47, its highest point in March this year. A surge above that level will point to more gains, potentially to $40.

SummaryRayonier is rated Buy with a $23.04 target, driven by asset value and a 5.5% dividend yield, over an 18–24 month horizon.My thesis emphasizes monetization of land, merger integration, and prudent NAV adjustments, rather than relying on a lumber sector rebound.Merger integration is key; $40 million in annual synergies are a goal, not a realized benefit, with cost reduction and cash conversion as priorities.Recent land transactions and real estate EBITDA guidance ($180–$200 million) are critical benchmarks for monitoring value realization and thesis validation. Taiyou Nomachi/DigitalVision via Getty Images

Thesis in a Nutshell Rayonier is offering a 21.4% margin at a price of $18.48, which raises it to my weighted target together with a 5.5% dividend, although it must be noted that this depends on the monetization of

18 Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

New deployment guide, informed by Vertiv and STL Partners research, helps organizations determine their AI archetypes and where the supporting infrastructure should be located

Workload-based approach connects business requirements to right-sized infrastructure models and reference designs to reduce deployment risks

, /PRNewswire/ -- Vertiv Holdings Co. (NYSE: VRT), a global leader in critical digital infrastructure, and Deloitte Center for Integrated Research today introduced a collaboration to help enterprises address a critical challenge in moving artificial intelligence from experimentation to production: determining where AI workloads should run and whether the available physical infrastructure can support them.

The new Vertiv Designing Infrastructure for Enterprise AI Guide, developed by Vertiv and STL Partners, a digital infrastructure research firm, provides business, IT and facilities leaders with a workload-based framework for making those decisions before committing to an infrastructure plan. Starting with the intended business outcome and AI workload, organizations can evaluate deployment location, infrastructure requirements and facility readiness, then align each workload with an appropriate physical infrastructure model and reference design for further planning and technical validation.

The underlying research highlights a critical consideration as enterprises move AI workloads into sustained production: infrastructure readiness can determine where workloads can be deployed and how quickly they can move into production. Available power, cooling, connectivity and operational capacity can determine whether a workload can be supported in an existing facility or requires a different deployment model.

The guide translates these considerations into a four-step process: (1) define the intended business outcome and AI workload, (2) evaluate the workload's scale, performance and operating requirements, (3) determine the most appropriate deployment location and (4) match the workload and location to a physical infrastructure model and reference design.

"The next phase of enterprise AI will be shaped not only by models and computing, but also by whether organizations can provide the power, cooling, connectivity and operating environment each workload requires," said Giordano Albertazzi, CEO of Vertiv. "By starting with the workload, enterprises can make infrastructure decisions earlier, identify constraints sooner and build a more credible path from AI ambition to production."

"The economics and operating requirements of AI change as workloads move into production," said Nicholas Merizzi, principal, Silicon2Service U.S. Lead, Deloitte Consulting LLP. "Organizations need to consider business value, governance, operating ownership and infrastructure together. Bringing those questions into the planning process earlier gives leaders a stronger basis for deciding where AI workloads should run and how they should be supported over time."

The process recognizes that enterprise AI is a portfolio of workloads rather than a single infrastructure decision. Exploratory workloads may remain in the cloud, while sustained or business-critical workloads may favor hybrid infrastructure or capacity managed by the enterprise. Workloads requiring faster response times, greater control, data proximity or specific model performance may need to run at the edge or in another controlled environment.

The workload-specific approach allows public cloud, colocation, enterprise-owned capacity, hybrid environments and edge infrastructure to each play a role. Rather than advocating broadly for or against the cloud, the guide provides a consistent method for determining the appropriate operating environment for each AI workload.

The research categorizes enterprise AI workloads into six archetypes covering model development, retraining and four categories of production use. These archetypes help organizations identify workloads with similar performance, operating and infrastructure requirements, creating a more consistent basis for planning. Each workload can then be aligned with one of four physical infrastructure models: Edge AI Cluster, Small AI Cluster, Large AI Cluster and High-Density AI Cluster.

The four models provide a starting point for decisions involving power, cooling, controls, connectivity, resilience, operational support and future growth. Corresponding reference designs can then be adapted based on site assessment, workload requirements and detailed engineering.

Facility readiness is critical across all four models. The guide helps enterprises evaluate whether a proposed location has sufficient power, cooling, connectivity, operational capacity and room for growth. Conducting this assessment early can help identify infrastructure constraints before they become barriers to deployment.

The full guide, Designing Infrastructure for Enterprise AI, details the six workload archetypes, four physical infrastructure models and a four-phase roadmap for planning, deploying and evolving enterprise AI infrastructure. It is available at https://www.vertiv.com/en-us/insights/industry/designing-infrastructure-for-enterprise-ai/.

About Vertiv Holdings Co. 
Vertiv Holdings Co. (NYSE: VRT) brings together hardware, software, analytics and ongoing services to enable its customers' vital applications to run continuously, perform optimally and grow with their business needs. Vertiv solves the most important challenges facing today's data centers, communication networks and commercial and industrial facilities with a portfolio of power, cooling and IT infrastructure solutions and services that extends from the cloud to the edge of the network. Headquartered in Westerville, Ohio, USA, Vertiv does business in more than 130 countries. For more information, and for the latest news and content from Vertiv, visit Vertiv.com.

Forward-looking statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27 of the Securities Act, and Section 21E of the Securities Exchange Act. These statements are only a prediction. Actual events or results may differ materially from those in the forward-looking statements set forth herein. Readers are referred to Vertiv's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q for a discussion of these and other important risk factors concerning Vertiv and its operations. Vertiv is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

For media inquiries, please contact:
Ruder Finn for Vertiv
E: [email protected]

SOURCE Vertiv Holdings Co

Agreement marks the Company’s second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction  | Source: Ultragenyx Pharmaceutical Inc.

NOVATO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million. Ultragenyx received the PRV upon U.S. Food and Drug Administration (FDA) approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known as UX111, the first-ever FDA-approved treatment for mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A).

“The sale of this PRV delivers meaningful non-dilutive funding that strengthens our ability to provide innovative treatments for rare and ultra-rare diseases while supporting our objective of achieving profitability,” said Howard Horn, chief financial officer and executive vice president, corporate strategy. “FAYUVI itself benefited from capital generated from a previous PRV sale, demonstrating the important role the PRV program plays in helping companies develop transformative therapies for rare disease patients.”

The closing of the PRV transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act.

Jefferies LLC is serving as exclusive financial advisor and Gibson, Dunn and Crutcher LLP is serving as legal counsel to Ultragenyx on this transaction.

About the Rare Pediatric Disease Priority Review Voucher Program
This U.S. FDA program is intended to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Under this program, a sponsor who receives an approval for a drug or biologic for a "rare pediatric disease" may qualify for a PRV that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor receives the PRV upon approval of the rare pediatric disease product application, and it can be sold or transferred.

About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Forward-Looking Statements and Use of Digital Media
Except for the historical information contained herein, the matters set forth in this press release, including statements relating to Ultragenyx’s expectations regarding the consummation and timing of the PRV transaction, the amount and receipt of the cash consideration, and the anticipated use and benefits of the proceeds, including advancing Ultragenyx’s pipeline and supporting its path to profitability, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve substantial risks and uncertainties that could cause Ultragenyx’s future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks and uncertainties relating to the satisfaction of the closing conditions for the PRV transaction, including expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, the possibility that the transaction may be delayed or may not close, Ultragenyx’s ability to realize the anticipated benefits of the transaction and use the proceeds as anticipated, the sufficiency of existing cash, cash equivalents and short-term investments to fund operations, the uncertainties inherent in clinical drug development and the regulatory approval process, risks related to serious or undesirable side effects of Ultragenyx’s products and product candidates, manufacturing risks, market acceptance, uncertainty related to insurance coverage and reimbursement, and the availability or commercial potential of Ultragenyx’s products and product candidates. Ultragenyx undertakes no obligation to update or revise any forward-looking statements.

For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx in general, see Ultragenyx’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 5, 2026, and its subsequent periodic reports filed with the SEC.

In addition to its SEC filings, press releases and public conference calls, Ultragenyx uses its investor relations website and social media outlets to publish important information about the company, including information that may be deemed material to investors, and to comply with its disclosure obligations under Regulation FD. Financial and other information about Ultragenyx is routinely posted and is accessible on Ultragenyx’s Investor Relations website (https://ir.ultragenyx.com/) and LinkedIn website (https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-/).

Ultragenyx Contacts

Investors
Joshua Higa
[email protected]

Media
Jess Rowlands
[email protected]

—Three Late-Breaking Abstracts at CHEST 2026 Deepen Understanding of the Potential of Treprostinil Palmitil Inhalation Powder (TPIP) Across Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)—

—New Analysis From the Phase 3 ASPEN Study at CHEST 2026 Provides Additional Insights on Bronchiectasis Management—

—Phase 3b ENCORE Study Findings at IDWeek 2026 Examine Amikacin and Macrolide Resistance Development in Patients With Newly Diagnosed Mycobacterium avium Complex (MAC) Lung Disease—

, /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced new data from its respiratory portfolio will be presented at the American College of Chest Physicians® Annual Meeting 2026 (CHEST 2026), taking place Oct. 18–21 in Phoenix, and IDWeek 2026, taking place Oct. 21–24 in Washington, D.C.

"This fall medical congress season is a powerful reminder of what's possible when we stay focused on delivering meaningful solutions for patients who need them most," said Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed. "From CHEST 2026 to IDWeek 2026, we're proud to share data across our respiratory portfolio, including BRINSUPRI, TPIP, and ARIKAYCE. Altogether, these presentations reflect the strength and diversity of our growing respiratory portfolio and our unwavering dedication to advancing critical therapies that have the potential to benefit the patients we aim to serve."

Insmed's Presence at CHEST 2026

Presentation highlights at CHEST 2026 include four abstracts from the treprostinil palmitil inhalation powder (TPIP) clinical development program, including three late-breaking abstracts that offer new insights into the long-term potential of TPIP in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Additionally, a post hoc analysis of the Phase 3 ASPEN study of BRINSUPRI® (brensocatib) — the first and only approved treatment for non-cystic fibrosis bronchiectasis (NCFB) — examines patient-reported sputum color and its association with neutrophil serine proteases and exacerbations.

The Insmed presentations at CHEST 2026 are as follows:

Top Late-Breaking Abstracts: New Drugs, New Targets, New Tools, Session ID 4145, Tuesday, Oct. 20, 2026, 11:15 a.m. MT to 12:15 p.m. MT (2:15 p.m. ET to 3:15 p.m. ET)

Functional Respiratory Imaging and Clinical Outcome Correlations With Treprostinil Palmitil Inhalation Powder (TPIP) Treatment for Pulmonary Arterial Hypertension (PAH) Late-Breaking Scientific Abstract Posters (B): Pulmonary Vascular Disease, Sleep Disorders, Poster 3219, Tuesday, Oct. 20, 2026, 1:45 p.m. MT to 2:30 p.m. MT (4:45 p.m. ET to 5:30 p.m. ET)

An Open-Label Extension (OLE) Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients With Pulmonary Arterial Hypertension (PAH): 1-Year Data From a 2-Year Study Late-Breaking Scientific Abstract Posters (B): Pulmonary Vascular Disease, Sleep Disorders, Poster 3224, Tuesday, Oct. 20, 2026, 1:45 p.m. MT to 2:30 p.m. MT (4:45 p.m. ET to 5:30 p.m. ET)

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)  Pulmonary Vascular Disease Scientific Abstract Posters (C): PAH, Poster 3503, Tuesday, Oct. 20, 2026, 1:45 p.m. MT to 2:30 p.m. MT (4:45 p.m. ET to 5:30 p.m. ET)

Clinical and Humanistic Burden of Pulmonary Hypertension Associated With Interstitial Lung Disease: Secondary Analysis of the Adelphi Disease Specific Programme Rapid Fire Original Investigation, CF and Non-CF Bronchiectasis Management, Session ID 4146, Monday, Oct. 19, 2026, 10:20 a.m. MT to 10:50 a.m. MT (1:20 p.m. ET to 1:50 p.m. ET)

Patient-Reported Sputum Color and Its Association With Neutrophil Serine Proteases and Exacerbations in Patients With Bronchiectasis: A Post Hoc Analysis From the ASPEN Trial Insmed's Presence at IDWeek 2026

Insmed will present two abstracts at IDWeek 2026 on ARIKAYCE® (amikacin liposome inhalation suspension), including data from the Phase 3b ENCORE study examining amikacin and macrolide resistance development in patients with newly diagnosed Mycobacterium avium complex (MAC) lung disease. A second presentation will examine real-world evidence on treatment drivers and outcomes in patients diagnosed with MAC lung disease.

Insmed presentations at IDWeek 2026 are as follows:

Antimicrobials, LB-2201.1, Thursday, Oct. 22, 2026, 10:30 a.m. ET to 10:42 a.m. ET

Amikacin and Macrolide Resistance in Patients with Newly Diagnosed Mycobacterium avium Complex Lung Disease: Results From ENCORE Respiratory Infections: Viral and Bacterial, P-475, Saturday, Oct. 24, 2026, 12:15 p.m. ET to 1:30 p.m. ET

Real-World Evidence of Treatment Drivers and Outcomes in Patients Diagnosed with Mycobacterium avium Complex Lung Disease (MACLD)  About ARIKAYCE 

ARIKAYCE® is approved in the United States as ARIKAYCE (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion, and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). Current international treatment guidelines recommend the use of ARIKAYCE for appropriate patients. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic that was historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function. Insmed's proprietary PULMOVANCE™ liposomal technology enables the delivery of amikacin directly to the lungs, where liposomal amikacin is taken up by lung macrophages where the infection resides, while limiting systemic exposure. ARIKAYCE is administered once daily using the Lamira® Nebulizer System manufactured by PARI Pharma GmbH (PARI).

About PARI Pharma and the Lamira® Nebulizer System 

ARIKAYCE is delivered by a novel inhalation device, the Lamira® Nebulizer System, developed by PARI. Lamira® is a quiet, portable nebulizer that enables efficient aerosolization of ARIKAYCE via a vibrating, perforated membrane. Based on PARI's 100-year history working with aerosols, PARI is dedicated to advancing inhalation therapies by developing innovative delivery platforms to improve patient care.

About BRINSUPRI 

BRINSUPRI® (brensocatib) is a small molecule, once-daily, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), designed to inhibit the activation of enzymes (neutrophil serine proteases) in neutrophils that are key drivers of chronic airway inflammation in non-cystic fibrosis bronchiectasis (NCFB). The therapy is approved in the United States as BRINSUPRI (brensocatib 10 mg and 25 mg tablets) and indicated for the treatment of NCFB in adult and pediatric patients 12 years of age or older. In the European Union and United Kingdom, BRINSUPRI (brensocatib 25 mg tablets) is approved for the treatment of NCFB in patients 12 years of age and older with two or more exacerbations in the prior 12 months. In Japan, BRINSUPRI Tablets 25 mg (brensocatib hydrate) is approved for the treatment of NCFB in adults and pediatric patients 12 years and older.

About TPIP

Treprostinil palmitil inhalation powder (TPIP) is an investigational dry powder formulation of treprostinil palmitil, a treprostinil prodrug consisting of treprostinil linked by an ester bond to a 16-carbon chain. Designed entirely in Insmed's laboratories, TPIP is a potentially highly differentiated prostanoid being developed as once-daily therapy for the treatment of patients with pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), progressive pulmonary fibrosis (PPF), and idiopathic pulmonary fibrosis (IPF). TPIP is administered in a capsule-based inhalation device. TPIP is an investigational drug product that has not been approved for any indication in any jurisdiction.

BOXED WARNING AND IMPORTANT SAFETY INFORMATION FOR ARIKAYCE IN THE U.S.

WARNING: RISK OF INCREASED RESPIRATORY ADVERSE REACTIONSARIKAYCE has been associated with an increased risk of respiratory adverse reactions, including hypersensitivity pneumonitis, hemoptysis, bronchospasm, and exacerbation of underlying pulmonary disease that have led to hospitalizations in some cases.

Hypersensitivity Pneumonitis has been reported with the use of ARIKAYCE in the clinical trials. Hypersensitivity pneumonitis (reported as allergic alveolitis, pneumonitis, interstitial lung disease, allergic reaction to ARIKAYCE) was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (3.1%) compared to patients treated with a background regimen alone (0%). Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids. If hypersensitivity pneumonitis occurs, discontinue ARIKAYCE and manage patients as medically appropriate.

Hemoptysis has been reported with the use of ARIKAYCE in the clinical trials. Hemoptysis was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (17.9%) compared to patients treated with a background regimen alone (12.5%). If hemoptysis occurs, manage patients as medically appropriate.

Bronchospasm has been reported with the use of ARIKAYCE in the clinical trials. Bronchospasm (reported as asthma, bronchial hyperreactivity, bronchospasm, dyspnea, dyspnea exertional, prolonged expiration, throat tightness, wheezing) was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (28.7%) compared to patients treated with a background regimen alone (10.7%). If bronchospasm occurs during the use of ARIKAYCE, treat patients as medically appropriate.

Exacerbations of underlying pulmonary disease has been reported with the use of ARIKAYCE in the clinical trials. Exacerbations of underlying pulmonary disease (reported as chronic obstructive pulmonary disease (COPD), infective exacerbation of COPD, infective exacerbation of bronchiectasis) have been reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (14.8%) compared to patients treated with background regimen alone (9.8%). If exacerbations of underlying pulmonary disease occur during the use of ARIKAYCE, treat patients as medically appropriate.

Anaphylaxis and Hypersensitivity Reactions: Serious and potentially life-threatening hypersensitivity reactions, including anaphylaxis, have been reported in patients taking ARIKAYCE. Signs and symptoms include acute onset of skin and mucosal tissue hypersensitivity reactions (hives, itching, flushing, swollen lips/tongue/uvula), respiratory difficulty (shortness of breath, wheezing, stridor, cough), gastrointestinal symptoms (nausea, vomiting, diarrhea, crampy abdominal pain), and cardiovascular signs and symptoms of anaphylaxis (tachycardia, low blood pressure, syncope, incontinence, dizziness). Before therapy with ARIKAYCE is instituted, evaluate for previous hypersensitivity reactions to aminoglycosides. If anaphylaxis or a hypersensitivity reaction occurs, discontinue ARIKAYCE and institute appropriate supportive measures.

Ototoxicity has been reported with the use of ARIKAYCE in the clinical trials. Ototoxicity (including deafness, dizziness, presyncope, tinnitus, and vertigo) were reported with a higher frequency in patients treated with ARIKAYCE plus background regimen (17%) compared to patients treated with background regimen alone (9.8%). This was primarily driven by tinnitus (7.6% in ARIKAYCE plus background regimen vs 0.9% in the background regimen alone arm) and dizziness (6.3% in ARIKAYCE plus background regimen vs 2.7% in the background regimen alone arm). Closely monitor patients with known or suspected auditory or vestibular dysfunction during treatment with ARIKAYCE. If ototoxicity occurs, manage patients as medically appropriate, including potentially discontinuing ARIKAYCE.

Nephrotoxicity was observed during the clinical trials of ARIKAYCE in patients with MAC lung disease but not at a higher frequency than background regimen alone. Nephrotoxicity has been associated with the aminoglycosides. Close monitoring of patients with known or suspected renal dysfunction may be needed when prescribing ARIKAYCE.

Neuromuscular Blockade: Patients with neuromuscular disorders were not enrolled in ARIKAYCE clinical trials. Patients with known or suspected neuromuscular disorders, such as myasthenia gravis, should be closely monitored since aminoglycosides may aggravate muscle weakness by blocking the release of acetylcholine at neuromuscular junctions.

Embryo-Fetal Toxicity: Aminoglycosides can cause fetal harm when administered to a pregnant woman. Aminoglycosides, including ARIKAYCE, may be associated with total, irreversible, bilateral congenital deafness in pediatric patients exposed in utero. Patients who use ARIKAYCE during pregnancy, or become pregnant while taking ARIKAYCE should be apprised of the potential hazard to the fetus.

Contraindications: ARIKAYCE is contraindicated in patients with known hypersensitivity to any aminoglycoside.

Most Common Adverse Reactions: The most common adverse reactions in Trial 1 at an incidence ≥5% for patients using ARIKAYCE plus background regimen compared to patients treated with background regimen alone were dysphonia (47% vs 1%), cough (39% vs 17%), bronchospasm (29% vs 11%), hemoptysis (18% vs 13%), ototoxicity (17% vs 10%), upper airway irritation (17% vs 2%), musculoskeletal pain (17% vs 8%), fatigue and asthenia (16% vs 10%), exacerbation of underlying pulmonary disease (15% vs 10%), diarrhea (13% vs 5%), nausea (12% vs 4%), pneumonia (10% vs 8%), headache (10% vs 5%), pyrexia (7% vs 5%), vomiting (7% vs 4%), rash (6% vs 2%), decreased weight (6% vs 1%), change in sputum (5% vs 1%), and chest discomfort (5% vs 3%).

Drug Interactions: Avoid concomitant use of ARIKAYCE with medications associated with neurotoxicity, nephrotoxicity, and ototoxicity. Some diuretics can enhance aminoglycoside toxicity by altering aminoglycoside concentrations in serum and tissue. Avoid concomitant use of ARIKAYCE with ethacrynic acid, furosemide, urea, or intravenous mannitol.

Overdosage: Adverse reactions specifically associated with overdose of ARIKAYCE have not been identified. Acute toxicity should be treated with immediate withdrawal of ARIKAYCE, and baseline tests of renal function should be undertaken. Hemodialysis may be helpful in removing amikacin from the body. In all cases of suspected overdosage, physicians should contact the Regional Poison Control Center for information about effective treatment.

U.S. INDICATION 

LIMITED POPULATION: ARIKAYCE® is indicated in adults, who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options. This drug is indicated for use in a limited and specific population of patients.

This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6. Clinical benefit has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Limitation of Use:

ARIKAYCE has only been studied in patients with refractory MAC lung disease defined as patients who did not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. The use of ARIKAYCE is not recommended for patients with non-refractory MAC lung disease.

Patients are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088. You can also call the Company at 1-844-4-INSMED.

Please see Full Prescribing Information. 

INDICATION AND IMPORTANT SAFETY INFORMATION FOR BRINSUPRI IN THE U.S.

U.S. Indication 

BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.

Important Safety Information

WARNINGS AND PRECAUTIONS

Dermatologic Adverse Reactions
Treatment with BRINSUPRI is associated with an increase in dermatologic adverse reactions, including rash, dry skin, and hyperkeratosis. Monitor patients for development of new rashes or skin conditions and refer patients to a dermatologist for evaluation of new dermatologic findings.

Gingival and Periodontal Adverse Reactions
Treatment with BRINSUPRI is associated with an increase in gingival and periodontal adverse reactions. Refer patients to dental care services for regular dental checkups while taking BRINSUPRI. Advise patients to perform routine dental hygiene.

Live Attenuated Vaccines
It is unknown whether administration of live attenuated vaccines during BRINSUPRI treatment will affect the safety or effectiveness of these vaccines. The use of live attenuated vaccines should be avoided in patients receiving BRINSUPRI.

ADVERSE REACTIONS
The most common adverse reactions ≥2% in the ASPEN trial included upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, and hypertension. The safety profile for adult patients with NCFB in WILLOW was generally similar to ASPEN, except for a higher incidence of gingival and periodontal adverse reactions.

Less Common Adverse Reactions
Liver Function Test Elevations
In ASPEN, there was an increase from baseline in average ALT, AST, and alkaline phosphatase levels at all time points from Week 4 through Week 56 in both BRINSUPRI 10 mg and 25 mg arms compared to placebo. The incidence of ALT >3X upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence of AST >3X ULN was 0.2%, 0.3%, and 0.5%; and the incidence of alkaline phosphatase >1.5X ULN was 2.5%, 4.1%, and 4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively.

Skin Cancers
In ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated patients.

Alopecia
In ASPEN, the incidence of alopecia among patients treated with BRINSUPRI 10 mg and 25 mg was 1.5% and 1.6%, respectively, compared to 0.4% in placebo-treated patients.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no clinical data on the use of BRINSUPRI in pregnant women.

Lactation: There is no information regarding the presence of BRINSUPRI and/or its metabolite(s) in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BRINSUPRI and any potential adverse effects on the breastfed child from BRINSUPRI or from the underlying maternal condition.

Pediatric use: The safety and effectiveness of BRINSUPRI for the treatment of NCFB have been established in pediatric patients aged 12 years and older. Common adverse reactions in pediatric patients aged 12 years and older enrolled in ASPEN were consistent with those in adults. The safety and effectiveness of BRINSUPRI have not been established in pediatric patients younger than 12 years of age.

Please see full US Prescribing Information.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines — including two approved therapies to treat chronic, debilitating lung diseases — as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.

Forward-looking Statements 

This press release contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking statements.

The forward-looking statements in this press release are based upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: risk that interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or may be interpreted differently if additional data are disclosed; failure to successfully conduct future clinical trials for our marketed products or our product candidates and our potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval of our product candidates; development of unexpected safety or efficacy concerns related to our marketed products or our product candidates; risks that our clinical studies will be delayed, that serious side effects will be identified during drug development, or that any protocol amendments submitted will be rejected; failure to maintain U.S., European, or Japanese approval for ARIKAYCE or BRINSUPRI; our inability to obtain full approval of ARIKAYCE from the FDA or our failure to obtain regulatory approval to expand ARIKAYCE's indication to a broader patient population; failure to obtain, or delays in obtaining, regulatory approvals for our product candidates in the U.S., Europe, or Japan or for ARIKAYCE outside of the U.S., Europe, and Japan, including separate regulatory approval for the Lamira® Nebulizer System in each market and for each usage; and failure to successfully commercialize our product candidates, if approved by applicable regulatory authorities, or to maintain applicable regulatory approvals for our product candidates, if approved.

The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company's forward-looking statements because, by their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For additional information about the risks and uncertainties that may affect the Company's business, please see the factors discussed in Item 1A, "Risk Factors," in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and any subsequent Company filings with the Securities and Exchange Commission (SEC).

The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Contact:

Investors:
Gianna De Palma
Associate Director, Investor Relations
[email protected]

Media:
Claire Mulhearn
Vice President, Corporate Communications
[email protected]

SOURCE Insmed Incorporated

AUDUBON, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will highlight its latest spine innovations at the 41st Annual North American Spine Society (NASS) Meeting in San Antonio, Texas, from October 14-17.

Globus Medical is continuing to expand its integrated spine ecosystem with technologies designed to connect patient-specific planning, implant solutions, and surgical execution across a range of spinal procedures. At NASS, the company will showcase SCRIPT™, its new patient-specific spinal implant platform, alongside the new XLIF™ Prone Procedural Solution featuring the XLIF™ Prone Patient Positioner and the MaXcess™ Air two-blade prone lateral retractor.

“We believe innovation is most meaningful when it connects technologies across the surgical workflow to support patient-specific planning and coordinated execution. Our focus is on developing an integrated ecosystem that helps surgeons translate their surgical plan in the operating room while supporting the clinical needs of each individual patient,” said Keith Pfeil, President and CEO.

SCRIPT™ marks Globus Medical’s expansion into patient-specific spine solutions. Within SCRIPT™ Studio, surgeons maintain control of preoperative planning and implant design, creating them while considering alignment, implant position, implant geometry, and fixation strategy. Plans generated from SCRIPT™ Studio can be imported into ExcelsiusGPS™ or ExcelsiusHub™ to integrate the preoperative plan with a navigated surgical workflow. SCRIPT™ will be featured in an exclusive preview at the Globus Medical technology suite, offering attendees an early look at this FDA-cleared technology as the company moves toward commercialization.

Globus Medical will also introduce the XLIF™ Prone Patient Positioner and MaXcess™ Air two-blade retractor as part of its XLIF™ Prone Procedural Solution. Bringing together patient positioning, lateral access, and enabling technologies, the solution is designed to support a connected workflow for prone lateral procedures. These new solutions combine adaptable patient positioning with stable, controlled lateral access to establish a reproducible workflow for prone lateral procedures. The XLIF™ Prone Patient Positioner allows adjustments in both the sagittal and coronal planes, while the MaXcess™ Air retractor provides a lightweight, rigid platform designed to support soft tissue management and stable access to the disc space.

Together, these technologies reflect Globus Medical’s continued investment in an integrated spine technology portfolio, connecting solutions across preoperative planning, patient-specific implants, procedural positioning, access, and surgical execution.

For more information on Globus Medical’s expanding spine portfolio, visit Globus Medical at NASS 2026, booth 315.

About Globus Medical, Inc.
Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies. Additional information can be accessed at www.globusmedical.com.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations, and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties, and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with health epidemics, pandemics, and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, the successful integration of businesses that we have acquired or may acquire in the future, and other risks. For a discussion of these and other risks, uncertainties, and other factors that could affect our results, refer to the disclosures contained in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”), including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our subsequent filings with the SEC. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Except as may be required by applicable law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. As used herein, the “Company,” “Globus”, “Globus Medical,” “we,” “us,” and “our” refers to Globus Medical, Inc.

Contact:

Shagun Singh
Senior Vice President, Strategy and Investor Relations
Phone: (610) 930-1800
Email: [email protected] | www.globusmedical.com

-

BETHESDA, Md.--(BUSINESS WIRE)--Walker & Dunlop, Inc. announced today that it has arranged a $110,000,000 refinancing for 1879 at the Grid and Arc at the Grid, two Class A multifamily properties totaling 731 units within a 192-acre mixed-use development in Stafford, Texas.

Walker & Dunlop Capital Markets Institutional Advisory arranged the loan as exclusive advisor to Lone Star Funds. Dustin Stolly, Aaron Appel, Keith Kurland, Jonathan Schwartz, Adam Schwartz, Sean Reimer, Michael Ianno, and Edward Leboyer arranged the floating-rate, interest-only loan from TPG Real Estate Credit.

“1879 at the Grid and Arc at the Grid are well-located multifamily assets that benefit from the continued growth of the Stafford and Sugar Land corridor,” said Stolly, senior managing director of Capital Markets Institutional Advisory at Walker & Dunlop. “TPG Real Estate Credit recognized the strength of the assets and their position within the Southwest Houston market, as well as Lone Star’s reputation as a best-in-class Sponsor, resulting in a financing solution that aligned well with our client’s objectives.”

Built in 2019 and 2020, respectively, 1879 at the Grid and Arc at the Grid span approximately 653,000 rentable square feet and 731 total units. Both properties feature a mix of studio, one-, two- and three-bedroom residences with modern finishes and open-concept layouts. Amenities include resort-style pools, fitness and wellness centers, resident lounges, coworking spaces, pet parks, outdoor lounges and courtyards, package lockers, detached garages and carports, barbecue areas and fire pits.

Located along the U.S. 90A corridor, 1879 at the Grid and Arc at the Grid offer direct access to Interstate 69, the Sam Houston Tollway and Highway 6, providing access to major Houston employment centers including the Texas Medical Center, Uptown/Galleria, Greenway Plaza, Downtown Houston and the broader Fort Bend County growth corridor. The Stafford and Sugar Land corridors are supported by continued population growth, a diverse employment base and established regional infrastructure.

In the first half of 2026, Walker & Dunlop’s Capital Markets team sourced over $13.9 billion from non-Agency capital providers, including nearly $9.6 billion for multifamily properties. This vast experience has made them a top advisor on all asset classes for many of the industry’s top developers, owners, and operators. To learn more about Walker & Dunlop’s broad financing options, visit our website.

About Walker & Dunlop

Walker & Dunlop (NYSE: WD) is one of the largest commercial real estate finance and advisory services firms in the United States and internationally. Our ideas and capital create communities where people live, work, shop, and play. Our innovative people, breadth of our brand, and our technological capabilities make us one of the most insightful and client-focused firms in the commercial real estate industry.

More News From Walker & Dunlop, Inc.

Back to Newsroom

SUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes 

, /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of the SUNRISE Phase 3 clinical program for oral VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.

The SUNRISE Phase 3 program includes two studies evaluating oral VK2735: one in adults with obesity and another in obese or overweight adults with type 2 diabetes. Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735, with patients receiving once-daily oral VK2735 for 68 weeks. SUNRISE-1 and SUNRISE-2 will each target enrollment of 560 adults. SUNRISE-1 will include obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) adults without type 2 diabetes who have at least one weight-related comorbidity. SUNRISE-2 will enroll adults with type 2 diabetes who are obese or overweight. Participants in both trials will be randomly assigned to one of four treatment groups receiving once-daily VK2735 doses of 27.5 mg, 35 mg, 55 mg, or placebo.

The primary endpoint of both trials is the percent change in body weight from baseline for participants receiving oral VK2735 as compared to placebo after 68 weeks of treatment. Secondary and exploratory endpoints will evaluate a range of additional safety and efficacy metrics, including the percentage of patients who achieve ≥ 5%, ≥ 10%, ≥ 15% or ≥ 20% body weight reduction from baseline. 

"Advancing the oral tablet formulation of VK2735 into Phase 3 is an exciting step toward expanding Viking's portfolio of therapeutic treatments for obesity," said Brian Lian, Ph.D., chief executive officer of Viking. "Oral VK2735 represents the most advanced oral dual GLP-1/GIP agonist in clinical development and has the potential to be positioned as either an induction therapy or in the maintenance setting, increasing the treatment options available to patients and clinicians. Obesity is a chronic disease that often requires long-term treatment, making convenience and ease of use important considerations for supporting patients throughout their treatment journey. We believe a once-daily oral therapy could offer a flexible dosing option that may support improved treatment adherence over time. Oral VK2735, together with our subcutaneous formulation, which is currently in the Phase 3 VANQUISH registration program, could provide clinicians and patients with greater choice in selecting an approach to weight loss and long-term management that best meets the needs of individual patients."

In 2025, Viking announced positive top-line results from the Phase 2 VENTURE-Oral Dosing study of the oral tablet formulation of VK2735 in obesity. The study successfully achieved its primary and secondary endpoints, with patients receiving once-daily oral VK2735 demonstrating clinically meaningful reductions in body weight compared with placebo. For the primary endpoint after 13 weeks of treatment, patients receiving oral VK2735 demonstrated statistically significant, dose-dependent reductions in mean body weight from baseline of up to 12.2%. Differences compared with placebo were statistically significant for all doses greater than 15 mg starting at Week 1 and were maintained throughout the study. Weight loss was progressive through Week 13 with no evidence of a plateau. Up to 97% of patients receiving oral VK2735 achieved at least 5% weight loss, and up to 80% achieved at least 10% weight loss, compared with 10% and 5% of patients receiving placebo, respectively.

Oral VK2735 also demonstrated encouraging safety and tolerability in the Phase 2 VENTURE-Oral study, with 98% of reported drug-related treatment-emergent adverse events (TEAEs) characterized as mild or moderate. Gastrointestinal (GI)-related events were the most commonly observed TEAEs and were consistent with the known effects of dual GLP-1/GIP receptor agonists. Across VK2735 treatment cohorts, GI-related events generally occurred early in treatment and subsided with continued dosing. Progressive dose escalation in 30 mg increments enabled participants to advance rapidly to higher dose levels while maintaining an encouraging tolerability profile.

In addition to the SUNRISE Phase 3 program, Viking is currently conducting a maintenance dosing trial of oral VK2735 and two Phase 3 studies evaluating subcutaneous VK2735 (VANQUISH-1 and VANQUISH-2). The VANQUISH trials are randomized, double-blind, placebo-controlled, multicenter trials designed to assess the efficacy and safety of subcutaneous VK2735 dosed weekly for 78 weeks. The VANQUISH-1 study is fully enrolled with approximately 4,500 adults who do not have type 2 diabetes and who have obesity (BMI ≥30 kg/m2) or are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. The VANQUISH-2 study is also fully enrolled with approximately 1,000 adults with type 2 diabetes who have obesity or are overweight. Patients in both trials are being randomized to one of four weekly VK2735 treatment arms of 7.5 mg, 12.5 mg, 17.5 mg, or placebo.

Correction Note: The company's press release issued on October 6, 2026, entitled, Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity, incorrectly stated that the trial would be evaluating, "weekly oral doses." The trial will be evaluating maintenance dosing options including daily oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo. 

About GLP-1 and Dual GLP-1/GIP Agonists

Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both. Semaglutide is a GLP-1 receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Ozempic®, Rybelsus®, and Wegovy®. More recently, research efforts have explored the potential co-activation of the glucose-dependent insulinotropic peptide (GIP) receptor as a means of enhancing the therapeutic benefits of GLP-1 receptor activation. Tirzepatide is a dual GLP-1/GIP receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Mounjaro® and Zepbound®.

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing a next-generation portfolio of therapies for obesity and metabolic disease. Guided by deep expertise in metabolic biology and rigorous science, Viking is developing innovative treatments to help people achieve meaningful, lasting health improvements by treating obesity first. The company's lead program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity. VK2735 is currently being evaluated in Phase 3 clinical studies for obesity, along with maintenance dosing strategies designed to support long-term weight management. Viking is also advancing additional obesity programs, including VK3019, an amylin receptor agonist, VK2809, an orally available thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD).

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its clinical and preclinical development programs, anticipated timing for reporting clinical data and cash resources.Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance.These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials, including those for VK2735, VK0214, VK2809, and the company's other incretin receptor agonists; risks that prior clinical and preclinical results may not be replicated; risks regarding regulatory requirements; and other risks that are described in Viking's most recent periodic reports filed with the Securities and Exchange Commission, including Viking's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings.These forward-looking statements speak only as of the date hereof.Viking disclaims any obligation to update these forward-looking statements except as required by law.

SOURCE Viking Therapeutics, Inc.

On Sept. 11, Oklo (OKLO -1.33%) launched an at-the-market (ATM) equity program to sell up to $1 billion in shares. While this is a normal way for pre-revenue companies to raise money, Oklo is doing it rather frequently.

The nuclear energy company has sold stock multiple times since going public via a merger with a special purpose acquisition company (SPAC) on May 10, 2024, resulting in significant dilution for early shareholders.

Image source: The Motley Fool.

At the close of Oklo's SPAC merger, it had about 122.1 million outstanding shares. The share count had jumped to 186 million by June 30, 2026, and the company issued another 7.3 million shares under its May equity program. That brings the total number of outstanding shares to roughly 192.3 million, a 58% increase from when it went public.

Shareholders who bought on day one and haven't sold now own about 37% less of Oklo than they originally did. In fairness, the share price is up 311% (as of Oct. 12), so those investors have still made a profit.

However, the company's share price has recently dropped significantly, and it hit a 52-week low on Oct. 8. This is especially problematic because it means Oklo needs to sell more shares than before to raise the same amount of money. The May program sold about 18 million shares to raise $1 billion. Oklo stock trades at about $35 at the time of this writing. At that price, raising $1 billion would take about 29 million shares.

Premium Feature

Moneyball Superscore

63/100

Today's Change

(

-1.33

%) $

-0.43

Current Price

$

31.78

Oklo is a high-risk, high-reward investment. One of the risks at this stage is significant shareholder dilution, which could continue until the company reaches profitability. If you've invested in Oklo or you're planning to invest, it's important to be aware of the risks and take a cautious approach.

Lyle Daly has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

, /PRNewswire/ -- Hippo Holdings Inc. (NYSE: HIPO) today announced that the company's third quarter financial results will be released before market open on Thursday, October 29, 2026. The company will host a conference call and live webcast for analysts and investors at 8:00 a.m. ET / 5:00 a.m. PT on that day. An earnings release with the financial results will be accessible from the investor relations section of the company's website prior to the conference call.

Third Quarter Earnings Conference Call and Webcast Information

Date: Thursday, October 29, 2026
Time: 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time
U.S. Toll-Free: +1 833-461-5787 / Global Dial-In Numbers
Meeting ID: 303199704
Webcast: https://events.q4inc.com/attendee/303199704

A replay of the webcast will be made available after the call in the investor relations section of the company's website at https://investors.hippo.com/

About Hippo

Hippo is a technology-native insurance group that uses its carrier platform to diversify risk across both personal and commercial lines. Through the Hippo Homeowners Insurance Program, the company applies deep industry expertise and advanced underwriting to deliver proactive, tailored coverage for homeowners. Hippo Holdings Inc. subsidiaries include Hippo Insurance Services, Spinnaker Insurance Company, Spinnaker Specialty Insurance Company, and Wingsail Insurance Company. Hippo Insurance Services is a licensed property casualty insurance agent with products underwritten by various affiliated and unaffiliated insurance companies. For more information, please visit http://www.hippo.com.

Contacts

Investors:
Charles Sebaski
[email protected]

Press:
Courtney Klosterman
[email protected]

SOURCE Hippo Holdings Inc.

SummaryTesla, Inc. remains a Hold as I await clarity on Cybercab regulatory risk and European software rollout.TSLA Q3 deliveries exceeded production, depleting inventory; Q4 will require higher output with little margin for error.Germany's support boosts the odds for EU-wide driver assistance software approval, offering meaningful future profit potential.Cybercab faces a critical NHTSA review; a production cap could materially limit TSLA stock upside and weigh on valuation. PonyWang/iStock Unreleased via Getty Images

I haven't liked Tesla, Inc. (TSLA) in a while, though it gave me a few reasons to reconsider last month.

Deliveries came in about 10,500 cars short of my bar, and the European vote I

5.1K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The S&P 500 hit a fresh record high last week, and it's trading at an elevated valuation as investors price in some very high forward expectations for artificial intelligence (AI) companies. As a result, strong corporate earnings are the key to keeping this bull market going, and most technology giants will report their latest quarterly results over the next month.

Google parent Alphabet (GOOG +0.16%)(GOOGL +0.30%) is scheduled to release its operating results for the third quarter (ended Sept. 30) on Oct. 28. Its stock happens to be reasonably valued heading into the report, and here's why I predict it could soar in the weeks and months that follow.

Image source: Alphabet.

Wall Street will be focusing on Google Search and Google Cloud
Alphabet is an incredibly diverse tech conglomerate, but Google Search and Google Cloud are currently its most important businesses. Search accounts for more than half of the company's total revenue, whereas Cloud is the fastest-growing segment.

There were some concerns that AI chatbots would disrupt traditional internet search engines like Google Search, but Alphabet introduced a series of AI features to transform the user experience. AI Overviews, for instance, use text and images to provide AI-generated responses to queries, which appear above the traditional search results. Then there is AI Mode, which opens a chatbot-style interface where users can expand on their original queries by asking additional questions.

During Alphabet's last quarterly conference call, CEO Sundar Pichai said AI Mode had surpassed 1 billion monthly users, and that these new features were driving an increase in Google Search usage overall. This means users are seeing more ads, which is why the platform generated a record $63.3 billion in revenue during the second quarter (ended June 30), up 17% year over year. Investors should look for a fresh update on how AI is improving the search business on Oct. 28.

Google Cloud is also coming off a record second quarter with revenues of $24.8 billion, which represented an accelerated growth rate of 84%. The platform provides its enterprise customers with access to computing capacity from state-of-the-art data centers, and a suite of ready-made foundation models, which are the primary ingredients for developing AI software. As of June 30, Google Cloud had a staggering $514 billion order backlog from customers who were waiting for Alphabet to build more AI infrastructure.

The backlog might be a good predictor of future revenue, so it's one of the main numbers Wall Street analysts will be looking at on Oct. 28. If it increased during the third quarter, it will be a sign that demand for AI computing capacity remains very strong.

Alphabet stock looks attractive heading into Oct. 28
Alphabet's second-quarter earnings soared by 294% year over year to $9.11 per share, mostly because of the Space Exploration Technologies (SPCX -4.21%) initial public offering (IPO) in June. Alphabet invested $900 million in SpaceX through a private placement in 2015, but accounting rules required the company to recognize the fair market value of its position after the IPO, which was over $90 billion as of June 30. Hence, there was a huge one-off increase to Alphabet's earnings, which had nothing to do with its operating performance.

With that out of the way, Wall Street's average estimate (provided by Yahoo! Finance) suggests Alphabet's earnings likely stabilized at around $3.02 per share in the third quarter, representing a more modest year-over-year growth rate of 5%.

Premium Feature

Moneyball Superscore

90/100

Today's Change

(

0.30

%) $

1.06

Current Price

$

353.78

It's disingenuous to value Alphabet based on its trailing-12-month earnings because of the inflated second-quarter result. But looking ahead, Wall Street thinks the company will generate earnings of $14.98 per share during 2027, placing its stock at a forward price-to-earnings (P/E) ratio of 23.4. That represents a slight premium to the Nasdaq-100 index which has a forward P/E of 22.1, but I think it's justified given the incredible AI-related strength in Google Search and Google Cloud.

Alphabet stock has returned around 45% over the past 12 months, but I think the company's third-quarter report will lay the groundwork for the next leg of upside, as long as its operating results show further momentum in the search and cloud businesses.

Delta Air Lines, the country's most profitable airline, has a problem serving its top-tier customers: not enough Porsches.

The airline uses a fleet of 40 of the luxury vehicles to drive its high-value flyers right to the plane.

"What's happened over the last several years is the demand has continued to rise, and we realized that the 40 cars that we have weren't enough to meet the demand. So we're moving that fleet to 70," Ranjan Goswami, Delta's chief marketing and product officer, told CNBC.

It's just one of many changes Delta is making for customers who fly in its most luxurious and expensive cabin, known as Delta One. The Porsche service is part of a VIP add-on option.

The carrier on Wednesday unveiled new crockery for the cabins, new Missoni mini pillows and fresh food and beverage menus, including Champagne served over sorbet and Blanton's bourbon. Many of the new items will appear on flights originating in Los Angeles later this month and on other routes in the coming months.

Delta is also planning to debut updated suites with a bigger screen and a more cushioned, lighter lie-flat seat when it starts flying its first Airbus A350-1000 planes early next year.

Delta didn't announce changes to the coach and premium economy cabins.

The airline's executives said the company is already thinking about adjustments on other aircraft, including smaller Airbus jets and on Boeing 787 Dreamliners that Delta has ordered and that will come in the next decade.

Delta has invested heavily in premium service for close to two decades, and United Airlines has followed suit for a little over 10 years. Other carriers are also leaning into demand for higher-priced options.

Read more about airlines' race to win over big spendersAlaska Airlines unveils massive premium cabin overhaul in high-end travel raceBudget airline king Bill Franke warms to first-class seats and premium upgradesUnited ditches more economy seats to make room for bigger premium cabins with new layoutsCaviar and privacy: Airlines' business-class wars are hereAmerican Airlines is arriving late to the luxury travel boom. Can it catch up?First-class seats are getting so fancy they’re holding up new airplanesAirlines can’t add high-end seats fast enough as travelers treat themselves to first class"You got to keep looking at the next cycle of what customers want, and you got to start planning for it now," Goswami said.

He said Delta focused on details and quality with its latest project for Delta One so that the items, from sliding suite doors to new Delta-logo-emblazoned dinnerware, are made to last. The company tested some of those items to check for chipping, but there are other challenges, like customers liking them too much.

"I think people are going to love a couple of items, although we hope they don't steal them," he said.

Read more CNBC airline newsWhy airfare could rise even more, but airline profits won’tBudget airline king Bill Franke warms to premium upgradesCompanies spurn airlines’ cheapest business class ticketsUnited’s next decision: What to do with all those Boeing 737 Max 10 seats it ordered years agoRecord heat, crowds drive offseason boom in international travel

Lowe's has doubled its quarterly dividend since 2021 and still outpaces Home Depot and Target on payout growth, but a frozen housing market and fresh acquisition debt are now squeezing the engine that makes those raises possible.

Lowe’s (NYSE:LOW | LOW Price Prediction) will send its next $1.25 quarterly dividend on November 4, 2026. The stock is down 21.86% year to date, which has lifted the yield to 2.53%. For retirees, the yield matters less than one question: can Lowe’s keep raising the payout while its biggest end market, housing, remains near a standstill?

Free Cash Flow Covers the Dividend Several Times Over
In fiscal 2025, Lowe’s produced $9.864 billion of operating cash flow and spent $2.213 billion on capex. That left about $7.65 billion of free cash flow. Dividends took $2.636 billion, roughly 34% of it. The forward dividend of $5 per share equals about 41% of management’s $12.25 adjusted EPS guidance.

The second quarter showed the same buffer. Brandon Sink put it simply during the August call:

“We generated $3.1 billion in free cash flow.”

Dividends paid in that quarter came to $673 million. The cash does come in unevenly through the year, though. In the quarter ending October 2025, operating cash flow was just $687 million against $673 million of dividends.

Lowe’s Is Raising Faster Than Home Depot and Target
In May, Lowe’s lifted its quarterly payout from $1.20 to $1.25, an increase of about 4.2%. Home Depot (NYSE:HD) raised its quarterly dividend just 1.3% to $2.33. Target (NYSE:TGT) managed 1.8%. Lowe’s quarterly payout has grown about 108% since the $0.60 it paid in early 2021. On the call, management tied the payout to its “commitment to returning capital to shareholders and our status as a dividend aristocrat.”

Housing Weakness Puts a Ceiling on Growth
Existing home sales slipped to 3.98 million in August, the low of the past year. Housing starts came in at 1.275 million. Lowe’s comparable sales rose only 0.2% last quarter, while transactions fell 2.1%. Marvin Ellison, the chief executive, was direct:

“Discretionary DIY demand remains under pressure.”

The push to win more professional contractors adds a second layer of housing risk. About 45% of the FBM acquisition’s business depends on residential construction, and the figure for ADG is 100%. Net interest expense is heading toward about $1.6 billion this year. Adjusted debt to EBITDA stands at 3.0 times, and management is aiming for 2.75 times by mid-2027. Big buybacks in past years, $14.124 billion in the fiscal year ending January 2023 alone, left shareholders’ equity at -$7.44 billion.

Our View: Lowe’s Keeps Growing the Payout, but More Slowly
Lowe’s remains a reliable dividend grower. Two things back that up. Buybacks fell to just $30 million in fiscal 2025, which leaves the dividend first in line for cash. And the payout uses only about a third of free cash flow.

The trade-off is speed. While the company pays down acquisition debt and housing stays soft, expect raises in the low-to-mid single digits rather than the big increases of 2021 and 2022 (we ranked ten long-streak dividend growers like Lowe’s by valuation in a free Dividend Kings report). Ellison is counting on a recovery:

“We know at some point we’re going to have to build houses in this country.”

The next hurdle is third-quarter results. Management expects adjusted EPS to come in about 7% below last year. Watch free cash flow and debt closely, because those two numbers will set the size of the next raise.

Contact [email protected] for any questions or corrections.

, /PRNewswire/ -- HUYA Inc. ("Huya" or the "Company") (NYSE: HUYA), a leading game-related entertainment and services provider, today announced that it recently received back-to-back industry accolades from two eminent business media brands, Barron's China and Forbes China. These honors highlight Huya's progress in its strategic transformation and its expanding role across the game ecosystem.

Huya was named to the Value Industry Benchmark 30 on the 2026 Barron's China Value List in the Integrated Game Ecosystem Services segment. The selection recognizes Huya's strong performance across the list's four assessment dimensions: Financial Integrity, Capital Quality, Pricing Power and Barron's Proprietary Data.

Huya also received a national award in the frontier innovation segment of the 2025 Forbes China Novel Intelligent Economy Selection for its creative use of AI and technological innovation to advance its game ecosystem and enhance its integrated game-related services.

Since launching its strategic transformation in August 2023, Huya has steadily expanded its game-related services, including game distribution, in-game item sales and game publishing. Goose Goose Duck mobile's successful debut and strong performance have validated Huya's content-led game publishing model, and The Legend of Swordman: Reunion and Xiao Xiao Qi Yu are progressing toward launch.

Huya is also advancing AI applications in live streaming, game tools and IP-based companionship. In July 2026, the Company unveiled VAM 1.0, its self-developed real-time multimodal digital human model, which can rapidly generate AI-powered virtual hosts capable of natural speech, singing, and expressive body movements, enabling lifelike, real-time interactions. VAM 1.0 is also expected to improve content production efficiency.

In the second quarter of 2026, Huya's total net revenues increased 11.0% year over year to RMB1,739.3 million. Game-related services, advertising and other revenues rose 54.1% to RMB637.9 million, representing 36.7% of total net revenues. Huya also doubled the authorized repurchase amount under its 2026 Share Repurchase Program to US$100 million.

Looking ahead, Huya will continue to drive innovation and strengthen its position as a leading game-related entertainment and services provider. Supported by a solid financial foundation, the Company aims to draw on its content ecosystem, streamer network, user base, AI technologies and industry partnerships to capture new growth opportunities and create long-term value for shareholders, users and industry partners.

About HUYA Inc.

HUYA Inc. is a leading game-related entertainment and services provider. Huya delivers dynamic live streaming and video content and a rich array of services spanning games, e-sports, and other interactive entertainment genres to a large, highly engaged community of game enthusiasts. Huya has cultivated a robust entertainment ecosystem powered by AI and other advanced technologies, serving users and partners across the gaming universe, including game companies, e-sports tournament organizers, broadcasters and talent agencies. Leveraging this strong foundation, Huya has also expanded into innovative game-related services, such as game distribution, in-game item sales, advertising and more. Huya continues to extend its footprint in China and abroad, meeting the evolving needs of gamers, content creators, and industry partners worldwide.

For more information, please visit: https://ir.huya.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, Huya's strategic and operational plans in this announcement contain forward-looking statements. Huya may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission ("SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Huya's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Huya's goals and strategies; Huya's future business development, results of operations and financial condition; the expected growth of the live streaming industry and the game industry in Chinese mainland and internationally; Huya's expectation regarding demand for and market acceptance of its products and services; Huya's ability to retain and grow its user reach, broadcasters, talent agencies, business partners for game-related services and advertisers; Huya's ability to expand its product and service offerings; competition in the live streaming industry and game industry; Huya's efforts in complying with applicable data privacy and security regulations; fluctuations in general economic and business conditions in China; the economy in China and elsewhere generally; any regulatory developments in laws, regulations, rules, policies or guidelines applicable to Huya; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in Huya's filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and Huya does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

In China:

HUYA Inc.
Investor Relations
Tel: +86-20-2290-7829
E-mail: [email protected] 

Piacente Financial Communications
Jenny Cai
Tel: +86-10-6508-0677
E-mail: [email protected] 

In the United States:

Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
E-mail: [email protected] 

SOURCE HUYA Inc.

Elon Musk just called unnamed memory makers extortionate while praising Micron's pricing as a model for long-term loyalty, but the company's own contracts tell a more complicated story about who actually controls prices.

At 5:52 p.m. Eastern on October 13, 2026, Elon Musk, responding to Nicholas Mugalli, posted on X that Micron Technology (NASDAQ:MU | MU Price Prediction) “has been reasonable regarding future memory prices, while others have been extortionate, which is something today’s customers won’t forget …” He named no company. No company was labeled extortionate. He added that Micron was making the smart move for long-term customer loyalty.

@RealNickMugalli Micron has been reasonable regarding future memory prices, while others have been extortionate, which is something today’s customers won’t forget …

Micron is making is the smart move for long-term customer loyalty.

— Elon Musk (@elonmusk) October 13, 2026

Micron had closed the regular session at $953.19, down 3.62%, and after hours it rose only 0.32% to $956.20. The praise read as commentary, and that take looks right.

What Musk’s Post Actually Covers
Nothing in the post is signed. No supply agreement between Micron and any Musk company has been reported, and the post disclosed no prices, volumes, or contract terms.

Musk was responding to investor Nicholas Mugalli. His post summing up a JPMorgan Chase (NYSE:JPM) note said Micron holds 26 long-term deals covering 35%+ of revenue through 2030, $150 billion in contracted backlog, $32 billion in committed customer cash and over 75% of next year’s output already sold. Those figures came through a social post. They didn’t come from the note itself, but they line up with what Micron told investors on its September 30 earnings call.

Why the Contracts Matter More Than the Compliment
Selling output years ahead turns a cyclical commodity business into something closer to a contracted one. That shift explains much of the re-rating that raised Micron’s market value to $1.08 trillion, close to Berkshire Hathaway’s (NYSE:BRK-A, NYSE:BRK-B) $1.11 trillion.

Against guidance for fiscal first-quarter revenue of $61.5 billion ± $1.5 billion, one buyer’s goodwill doesn’t move the numbers. Musk also has a stake in the matter. His companies buy huge amounts of memory for AI computing and vehicles (we featured seven suppliers behind that same AI expansion, from power to cooling, in a free report you can grab here). When a buyer that size praises a supplier for gentle pricing, he is also negotiating in public.

Where the “Reasonable” Label Breaks Down
Micron posted an 87.0% non-GAAP gross margin (the share of revenue left after production costs) in the fiscal fourth quarter. Management said, “any new discussions on SCAs where pricing is involved are negotiated with higher pricing based on prevailing market conditions and outlook.”

The pricing bands limit both the downside and the upside. Three quarters of the expected contract revenue come with a set pricing framework, and most of those frameworks carry floor and ceiling prices. Ceilings cap the upside during a shortage, but the finance chief said: “even at floor prices, we expect margins meaningfully above any prior cycle peak margins.”

The bigger threat is supply, because before Musk posted, a Chinese memory maker flagged a denser chip design, which goes straight at the scarcity thesis for commodity DRAM. Micron fell 12.4% over four sessions from $1,088.00, and it now trades 24% below its $1,255.00 high even after a 234.18% gain this year.

What Investors Need to Weigh in Micron’s Contract Story
The pullback likely reflects worry about future Chinese supply, while Micron’s contracts are cash-backed take-or-pay agreements (the customer pays whether or not it takes delivery) that run into 2031. Musk’s post doesn’t change any contract already signed, and investors were right to shrug, since the pricing control he praised is narrower than it sounds because Micron is raising prices on new agreements.

Memory cycles can turn fast, and output sold forward at today’s prices may look cheap if the shortage gets worse while Chinese competition grows. Micron’s fiscal first-quarter report needs to land inside its $61.5 billion ± $1.5 billion range at roughly 86.25% gross margin. A miss on either number, or a close back below the $186.25 low that started this run, would prove this view wrong.

Contact [email protected] for any questions or corrections.

-

BOSTON--(BUSINESS WIRE)--State Street Corporation (NYSE: STT) reported its third-quarter 2026 financial results today. The news release, presentation and additional financial information can be accessed on State Street’s Investor Relations website, http://investors.statestreet.com. A conference call to discuss the firm’s financial results, outlook and related matters will be held at 11:00 a.m. ET today, Wednesday, October 14, 2026. The call will be open to the public.

The conference call will be accessible on State Street’s Investor Relations website, and by telephone at (+1) 800 439 6511 (Participant Passcode: 96234#).

Following the conference call, a replay will be available on State Street’s Investor Relations website for approximately one month.

About State Street Corporation
State Street Corporation (NYSE: STT) is one of the world's leading providers of financial services to institutional investors including investment servicing, investment management and investment research and trading. With $59.2 trillion in assets under custody and/or administration and $6.3 trillion* in assets under management as of September 30, 2026, State Street operates globally in more than 100 geographic markets and employs approximately 51,000 worldwide. For more information, visit State Street's website at www.statestreet.com.

*Assets under management as of September 30, 2026 includes approximately $172 billion of assets with respect to SPDR® products for which State Street Global Advisors Funds Distributors, LLC (SSGA FD) acts solely as the marketing agent. SSGA FD and State Street Investment Management are affiliated.

More News From State Street Corporation

Back to Newsroom

 | Source: Ocugen

Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapiesExpands access to a potential one-time gene therapy for retinitis pigmentosa in a region with high disease prevalence and substantial unmet needAgreement includes upfront license fee and initial development payments up to $4 million, potential sales milestones up to $255 million, and royalties equaling 22% of net sales; Ocugen will manufacture and supply OCU400 MALVERN, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the execution of a licensing agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for the treatment of Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region.

Subject to the terms of the License Agreement, Ocugen will receive an upfront license fee and potential initial development milestone payments of up to $4 million, in the aggregate, as well as potential sales milestone payments of up to $255 million, and royalties equaling 22% of OCU400 net sales generated by Roots Pharmaceutical. Ocugen will manufacture the commercial supply of OCU400 under terms of a related supply agreement.

Ocugen believes RP is a leading cause of inherited vision loss globally, with a particularly significant unmet need across the MENA region, where the prevalence of RP is estimated to be 10 to 20 times higher than in the U.S. and EU. Through OCU400, Roots Pharmaceutical aims to help address this substantial unmet need by potentially providing a treatment option for people in the MENA region living with RP and facing progressive vision loss and potential blindness.

“By partnering with Roots Pharmaceutical, an established leader with strong reach across the Middle East and North Africa, we are expanding our ability to bring our potential one-time gene therapy to patients in a region where retinitis pigmentosa is highly prevalent and the unmet medical need is significant,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-founder of Ocugen. “This agreement represents another important step in our strategy to build strong regional partnerships and expand global access to our potentially transformational gene therapies.”

Roots Pharmaceutical is an established and rapidly growing pharmaceutical company serving key markets across the MENA region. With more than two decades of operating experience and expertise in commercializing innovative medicines, the company’s regional capabilities and established healthcare relationships position it as a strong partner for bringing OCU400 to RP patients across MENA.

"This partnership reflects Roots' commitment to bringing breakthrough gene therapies to the Middle East and North Africa, leading and shaping the treatment paradigm for our patients, which is our main objective," said Dr. Islam Zayed, Chief Executive Officer and Co-Founder of Roots Pharmaceutical. "OCU400 has the potential to change the outlook, and the lives, of patients living with retinitis pigmentosa. We look forward to working closely with Ocugen to build the diagnosis-to-treatment pathway that gene therapy requires across our markets, and to exploring further collaboration across Ocugen's ophthalmology pipeline."

Ocugen continues to advance OCU400 through its Phase 3 liMeliGhT clinical trial with a topline data readout expected in the first quarter of 2027, followed by global regulatory submissions, including a Biologics License Application in the U.S. and a Marketing Authorization Application in Europe.

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow the Company on LinkedIn and X.

About Roots Pharmaceutical Company
Founded in Kuwait in 2006, Roots Pharmaceutical is a fully integrated healthcare provider specializing in commercializing innovative therapies, medical devices, and an aesthetic line across the Middle East and North Africa. It is led by a team with over 25 years of pharmaceutical industry experience.

Roots Pharmaceuticals has established a direct commercial presence in the MENA region (Middle East and North Africa), mainly in GCC countries and key North African countries, with a therapeutic portfolio spanning neurology, hematology, oncology, rare diseases, dermatology, cardiovascular, medical devices and aesthetic line.

With 30+ global partners and a $300M+ product pipeline, Roots Pharmaceutical and its strategic partner Al-Dhow Group are committed to delivering meaningful healthcare impact across the MENA region through innovation, access and excellence. Its operations are ISO 9001:2015-certified and externally audited by PwC.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits to Ocugen of the definitive license agreement and supply agreement with Roots Pharmaceutical Company, as well as statements regarding strategy, the potential amounts of milestone payments and royalty payments that may be received under the license agreement, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical and clinical development of Ocugen’s product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, including the timing of data readouts and marketing applications, the ability to initiate new clinical programs, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, statements regarding potential market size and commercial possibilities of Ocugen’s product candidates, which are subject to risks and uncertainties. Ocugen may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from Ocugen’s current expectations, including, but not limited to, the risks that the license agreement and supply agreement with Roots Pharmaceutical Company will not lead to the current anticipated benefits to Ocugen; that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing may not be predictive of the results or success of later clinical trials; and that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in Ocugen’s filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that Ocugen files with the SEC. Any forward-looking statements that Ocugen makes in this press release speak only as of the date of this press release. Except as required by law, Ocugen assumes no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contacts:

Investors:
Candice Masse, astr partners
[email protected]

Media:
Chris Clark, Ocugen
[email protected]

Applied Materials just posted its fifth consecutive earnings beat while the stock cratered 22% in three months, and at least one Wall Street firm thinks that disconnect points to one of the more compelling setups in the chip equipment sector…

Applied Materials (NASDAQ:AMAT | AMAT Price Prediction) currently trades at $464.24, while Wall Street’s average price target stands at $635.33. That gap implies 36.9% upside.

Applied Materials builds the deposition, etch, inspection and packaging tools that chipmakers use to produce AI processors and high-bandwidth memory. Its latest quarter delivered revenue of $9.115 billion, up 24.8% year over year, and non-GAAP EPS of $3.50 against a $3.39 consensus. That was its fifth consecutive beat.

The business is accelerating while the stock falls, and investors need to know whether the market sees something analysts are missing.

An Investor Day Omission Deepened a 22% Three-Month Slide
Applied Materials declined to provide an industry spending forecast at its investor day, and shares fell 6.69% in a single session. Barron’s noted the stock was on pace to close lower for a sixth consecutive trading session. The one-week loss reached 12.45%, and the three-month decline stands at 21.98% from $595.06. Shares now sit 37.2% below their 52-week high of $738.88.

The pressure started earlier. Reuters reported that shares slipped after the August earnings report as an upbeat outlook failed to soothe investors seeking faster growth after a stellar run. Management also highlighted a hard constraint on the call: “It will be the availability of clean room at a high level that will determine what we can all ship next year.” With no spending forecast on offer, investors had to price that uncertainty themselves.

The weakness hit the whole group, but Applied took the most damage. Lam Research (NASDAQ:LRCX) fell 2.73% and KLA (NASDAQ:KLAC) dropped 3.22% on the same day, while the S&P 500 slipped just 0.01%.

Analysts Keep Raising Estimates as the Stock Falls
Analysts are focused on to AI-driven demand that management says stretches years out. Applied expects leading-edge foundry logic, DRAM and advanced packaging to represent “around 80% of wafer fab equipment growth in 2026 and 2027,” and projects packaging revenue to grow “more than 70% in calendar 2026.” DRAM revenue, including HBM packaging, grew 52% year over year. Fiscal Q4 guidance calls for revenue of about $10.25 billion and non-GAAP EPS of roughly $4.02. Customer visibility now includes “some conversations now extending to 2030.”

Revisions point higher. The fiscal 2027 EPS consensus has rose to $18.4658 from $16.5279 90 days ago, and the January-quarter estimate drew 18 upward revisions in the past week with none lower. The top fiscal 2027 estimate reaches $21.77, which supplies the earnings math behind the most aggressive near-doubling calls by HC Wainwright, with its $900 target price. Ratings break down as 4 Strong Buy, 29 Buy, 7 Hold and no Sells.

Rising estimates coupled with a falling price signal multiple compression, and at 23x forward earnings the stock still prices in sustained growth. Analyst targets are 12-month opinions and carry no guarantee.

Chip Equipment Peers Fell Together, and Applied Fell Hardest
The semiconductor equipment group sold off as a pack, so Applied belongs to a broader falls. It has simply dropped further.

Lam Research lost 9.82% over the past week. The stock trades at $301.11, versus a $375.81 average target, implying 24.8% upside. Ratings show 4 Strong Buy, 25 Buy and 6 Hold with no Sells. Wall Street sees less upside here than for Applied.

KLA fell 6.82% over the week and trades at $184 versus a $232.77 target, implying 26.5% upside. Its 5 Strong Buy, 14 Buy and 10 Hold ratings make it the most carefully rated name of the group. Its upside also trails Applied’s.

Western Digital (NASDAQ:WDC) is an adjacent AI-infrastructure play that sells hard drives. It has fallen 32.4% over three months. The shares trade at $380.71 versus a $668.50 target, implying 75.6% upside, with 4 Strong Buy, 17 Buy and 5 Hold ratings. Melius Research has the highest target on the Street at $1,050.

Western Digital carries the largest implied upside of the group. Among direct equipment peers, Applied offers the widest gap to consensus.

An 81% Year-to-Date Gain Still Leaves the S&P 500 Far Behind
Applied trades at $464.24 against a consensus target of $635.33, implying 36.9% upside across 40 analysts. The three-month decline of 21.98% sits alongside a 1.7% one-month gain, showing the damage arrived in two sharp waves.

Year to date, Applied is up 81.29% while the S&P 500 has gained 14.1%. Over one year, the stock has returned 112.71% against 17.35% for the index. The 50-day moving average of $489.74 now sits above the share price, with the 200-day average at $435.51.

Applied Materials Bull and Bear Cases Hinge on the 2027 Spending Outlook
Shares look more compelling if DRAM and advanced packaging ramp as guided and fiscal Q4 lands near $10.25 billion. That keeps the $18.4658 fiscal 2027 EPS path intact and makes a forward multiple near 23x look reasonable for this growth rate. A clear 2027 spending outlook would also remove the uncertainty behind this week’s drop.

The bear case gains weight if clean room shortages cap shipments, export controls squeeze China sales, or the investor day silence signals a weaker 2027 than analysts model. China already declined to 28% of revenue from 35%.

On balance, the data leans positive. Estimates are rising, guidance points higher, and the stock trades 37.2% off its high. The missing forecast is a real yellow flag, so management’s 2027 outlook is the next data point to keep an eye on.

Contact [email protected] for any questions or corrections.

Thomson Reuters launches the next generation of CoCounsel Legal globally, adding cross-border legal research from more than 100 countries and territories in a single workflow. 

, /PRNewswire/ -- Thomson Reuters (Nasdaq: TRI) (TSX: TRI), a global content and technology company, is making things simpler for legal professionals working across borders. The pressure to move faster, advise with greater confidence, and navigate requirements that span multiple countries and legal systems, while never compromising the professional standard their work demands, has never been greater.  

Thomson Reuters is solving that with the new Multinational Profile, a capability that brings legal content from more than 100 countries and territories into a single CoCounsel Legal workflow. It helps legal teams research cross-border legal and compliance questions without leaving the platform they already trust. The new capability is available in the next generation of CoCounsel Legal, and the upgraded platform will be available to customers in more than 90 countries and territories throughout 2026. Customers in countries including Australia, Canada and the United Kingdom will soon have access to the fully agentic platform built around how legal work happens, grounded in the trusted authority of Westlaw and Practical Law. 

These announcements are only possible because of what Thomson Reuters has spent 175 years building: authoritative legal content across jurisdictions, hard-won trust in its Fiduciary-Grade AI™ technology, and an ongoing commitment to serving the legal profession globally. Few companies could bring together legal content spanning so many countries and territories, the professional expertise to make it useful, and the platform scale to deliver it. Thomson Reuters can.  

Introducing the CoCounsel Legal Multinational Profile 

Until now, researching a cross-border legal question meant leaving CoCounsel Legal to find, evaluate, and reconcile information from multiple sources across jurisdictions, with no guarantee any of them met a professional standard. The new Multinational Profile changes that. It brings cross-border legal research into a single CoCounsel Legal workflow. Legal teams can research legal requirements across countries, compare key differences, identify issues that may require local advice, and trace every finding to its underlying source, all without switching tools or rebuilding context from scratch. 

The Multinational Profile draws on Thomson Reuters globally trusted legal content and vetted official legal and regulatory sources, delivering responses that legal professionals can examine, verify, and act on. Legal teams gain a better-informed foundation for cross-border analysis while retaining full visibility into the sources behind answers and the ability to identify where deeper review or local counsel is required. 

"Ask any lawyer whose work crosses borders what slows them down and you will hear the same answer: the research tools stop at the border," said David Wong, Chief Product Officer, Thomson Reuters. "They piece together sources from multiple platforms with no guarantee the result meets the professional standard their work demands. The Multinational Profile changes that, and Thomson Reuters has the scale, the content, and the expertise to deliver it. The professional standard now travels with the work, wherever the matter takes it." 

Next Generation CoCounsel Legal Goes Global 

Legal professionals globally will soon have access to the next generation of CoCounsel Legal, with key capabilities including:  

Market-Leading Research: Combines advanced AI with trusted Westlaw and Practical Law content to produce comprehensive legal research reports that surface key authorities, relevant precedents, and actionable insights. 

Workspaces: Create matter-specific workspaces that bring together firm documents, legal department materials, precedents, and institutional knowledge. Context is preserved across tasks and matters to support more informed analysis. 

Tabular Analysis: Enables attorneys to bulk review documents and ask questions simultaneously. Results are delivered in a dynamic, filterable table with supporting references linked to source materials for validation. 

Integrations with the tools lawyers use every day: CoCounsel Legal connects with document management systems and productivity tools, helping professionals access relevant information where work already takes place. Available integrations vary by country. 

Not every capability is available in every geography, and availability will continue to expand. 

"When we evaluate technology, the question is whether it will genuinely work for our lawyers and stand up to professional scrutiny," said Steve Savage, Partner and CTO & Head of Development at Gosschalks. "The next generation of CoCounsel Legal is a leap forward in both functionality and quality of output, grounded in the authority of Westlaw and Practical Law. Our time in the beta made the difference clear, and it's encouraging to see Thomson Reuters bringing that to firms around the world." 

Availability 

The next generation of CoCounsel Legal is available now in the United Kingdom, with general availability expected globally in countries including Australia, Brazil, Canada, Singapore, and the United Arab Emirates by the end of October 2026. 

The Multinational Profile will become available to customers in the U.S., Europe, UK, Canada and Australia throughout October.  

Visit our website for more information on the Multinational Profile.   

About Thomson Reuters 

Thomson Reuters (TSX/Nasdaq: TRI) informs the way forward by bringing together the trusted content and technology that people and organizations need to make the right decisions. The company serves professionals across legal, tax, audit, accounting, compliance, government, and media. Its products combine highly specialized software and insights to empower professionals with the data, intelligence, and solutions needed to make informed decisions, and to help institutions in their pursuit of justice, truth and transparency. Reuters, part of Thomson Reuters, is the world's leading provider of trusted journalism and news. For more information, visit thomsonreuters.com 

Media Contact 

David Greenberg
Senior Manager, AI and Innovation Communications
[email protected]

SOURCE Thomson Reuters

, /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Celsius Holdings, Inc. ("Celsius" or "the Company") (NASDAQ: CELH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of CELH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: February 21, 2025 to June 3, 2026

DEADLINE: November 3, 2026

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Celius failed inform consumers about the potential health risks of its Alani Nu drinks. The Company marketed Alani Nu drinks to consumers under the age of 18 who were susceptible to these health risks. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Celsius, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE Schall, Brown & Schwartz LLP

Summary

“PowerTitan 3.0 represents Sungrow’s continued innovation in advanced energy storage system design,”

As AI-driven electricity demand accelerates worldwide, utilities and energy providers are under growing pressure to store and deliver energy more efficiently. Battery energy storage system (BESS) providers are seeking advanced power conversion technologies to improve performance and system economics. To address these needs, Sungrow has adopted onsemi’s latest SiC hybrid power module technology for its PowerTitan 3.0 energy storage platform. The design improves system efficiency, helping utilities and energy providers increase usable energy output while lowering operating costs.

News Highlights

onsemi’s EliteSiC hybrid power module enables the highest-density battery energy storage system deployments, helping energy providers meet growing electricity demand from AI, renewable energy and electrificationNew BESS architecture improves inverter-level efficiency by 0.4%, helping maximize energy delivered to the grid while reducing losses and improving reliabilitySungrow’s PowerTitan 3.0 energy storage platform integrates onsemi’s latest EliteSiC hybrid power module technology, optimized for high-power DC-AC energy conversion in utility-scale battery storage applications SCOTTSDALE, Ariz., Oct. 14, 2026 (GLOBE NEWSWIRE) -- onsemi (Nasdaq: ON) today announced that Sungrow, a global leader in renewable energy technology, has adopted onsemi’s latest EliteSiC silicon carbide (SiC) hybrid power module technology for the Sungrow PowerTitan 3.0 energy storage platform. The integration enables improved efficiency and enhanced system performance for utility-scale battery energy storage systems (BESS).

Helping Sungrow Deliver More Usable Energy

The PowerTitan 3.0 platform incorporates onsemi’s high-density power integrated modules (PIMs), optimized for advanced three-level inverter architectures used in high-power energy storage applications.

Compared with the previous-generation platform, the new architecture improves inverter-level efficiency by 0.4%, enabling higher-power battery storage deployments without sacrificing efficiency. The architecture supports power conversion units rated up to 450 kW, contributing to the platform’s increased power density and higher-power deployment capability.

With the performance advantages of SiC, the solution supports key system-level benefits including:

Peak efficiency exceeding 99.3% to reduce energy loss in utility-scale systemsIncreased power density supports higher-power BESS deploymentsEnhanced thermal performance supports reliable operation in high-power applicationsImproved system economics through a hybrid SiC design optimized for large-scale deployment The design win builds on a long-standing strategic relationship between onsemi and Sungrow. Through extensive engineering and validation activities, the companies collaborated throughout platform definition, system optimization and qualification to meet the demanding performance requirements of next-generation energy storage deployments.

“PowerTitan 3.0 represents Sungrow’s continued innovation in advanced energy storage system design,” said Chen Peng, General Manager of Energy Storage Conversion Product Line at Sungrow Energy Storage Business Unit. “By integrating advanced technologies and collaborating with strategic partners such as onsemi, Sungrow is accelerating the deployment of higher-performance storage solutions that deliver greater value throughout the lifecycle of energy assets. With growing market recognition, Sungrow estimates delivering 10 GWh of PowerTitan 3.0 across Europe in 2026, further supporting the region’s transition toward a more flexible and resilient energy system.”

“At utility scale, even small improvements in power conversion efficiency can have a meaningful impact on battery energy storage system (BESS) performance and total cost of ownership,” said Sergio Fissore, Vice President and General Manager, IPD Power Division, onsemi. “Our EliteSiC hybrid power module enables higher-efficiency, higher-density energy storage systems that help maximize usable energy and improve system reliability. Together with Sungrow, we're advancing the power conversion technologies needed to support the next generation of energy infrastructure.”

Why Fractions of a Percent Matter

At utility scale, even small efficiency improvements can generate meaningful financial and environmental benefits. According to onsemi analysis, a 0.4% efficiency improvement delivered by the new SiC hybrid module could save more than 475 MWh of energy annually in a 100 MW battery energy storage installation compared with the previous-generation module.

Those energy savings can help reduce operating costs, increase usable energy delivered to customers and lower overall emissions. The architecture also enables higher overload capability and improved thermal performance, helping customers extract more usable energy from every storage asset.

Supporting the Infrastructure Behind the AI Era

Utilities and energy providers are seeking ways to store more energy, reduce conversion losses and improve overall system economics to meet unprecedented demand amid the AI infrastructure buildout and electrification transition.

Industry forecasts project the battery energy storage market will more than double by 2030 as utilities invest in infrastructure needed to support increasing electricity demand and renewable energy deployment. At the same time, energy storage providers are moving toward higher-power, higher-voltage architectures to improve system economics.

Additional Information

High-Density Si/SiC Hybrid Power Integrated Module (PIM) Product PageSi/SiC Hybrid PIM Product PortfolioEnergy Storage System SolutionsEliteSiC Technology PageEliteSiC M3e Product PageInsulated Gate Bipolar Transistors (IGBTs) Products Page About onsemi
onsemi (Nasdaq: ON) delivers intelligent power and sensing technologies that enable electrification, energy efficiency, safety, and automation across automotive, industrial, and AI data center end-markets. With a highly differentiated and innovative product portfolio, onsemi helps customers solve complex challenges to achieve higher efficiency, improved performance, and lower system cost, while supporting a safer, cleaner, and more energy‑efficient world. The company is part of the S&P 500® index. Learn more at www.onsemi.com.

onsemi and the onsemi logo are trademarks of Semiconductor Components Industries, LLC. All other brand and product names appearing in this document are registered trademarks or trademarks of their respective holders. Although the Company references its website in this news release, information on the website is not to be incorporated herein.

Contact:
onsemi
Michael Mullaney
[email protected]
+1 838-289-7314

14.10.2026 12:37, BAAMACIN

Skupina M2C zveřejnila v rámci Start Day aktualizovaný celoroční výhled. Společnost letos očekává meziroční růst nekonsolidovaných provozních výnosů o 37,4 % na 6,98 mld. Kč. K tomuto růstu by měly přispět plánované akvizice a provozní výkonnost. Provozní zisk EBITDA by měl dosáhnout 140 mil. Kč, což je blízko horní hrany výhledu, který společnost poskytla na jarním Start Day.

Výhled Společnost očekává v celém roce nekonsolidované provozní výnosy ve výši 6,98 mld. Kč. Jednalo by se tak o meziroční růst o 37,4 % vůči 5,08 mld. Kč v roce 2025. Výhled zahrnuje akvizice a jeho předpokladem je dokončení rozjednaných akvizic do konce roku. Podle managementu je zhruba 300 až 400 mil. Kč z plánovaného obratu závislých na dosud neobjednaných vícepracích, jejichž objem ani načasování společnost přímo neovlivňuje. Tuto část predikce proto označila za odhad, nikoli závazek. Generální ředitel Matěj Bárta na konferenčním hovoru komentoval, že na rozdíl od ostatních společností je těžké pro M2C predikovat odběry vzhledem k odvětví ve kterém společnost působí.

V rámci jarního Start Day společnost pro letošek očekávala konsolidované tržby v rozmezí 4,7 až 5,0 mld. Kč. Aktuální výhled se však týká nekonsolidovaných provozních výnosů, a není proto s jarním výhledem přímo srovnatelný.

Očekávaný přírůstek provozních výnosů podle zemí, zdroj: M2C

Předpokládaný provozní zisk EBITDA by měl dosáhnout 140 mil. Kč, což je blízko horní hrany výhledu, který společnost komentovala v rámci jarního Start Day v intervalu 123 až 143 mil. Kč.

Celou prezentaci společnosti z podzimního Start Day naleznete pod odkazem zde.

Akcie M2C Akcie společnosti M2C (BAAMACIN) se na pražské burze obchodují za 135 Kč. Na RM-SYSTÉMu se akcie obchodují za 136 Kč.

Zdroj: M2C

Michal Bárta, Fio banka, a.s.

According to Interbrand, Nike (NKE -0.06%) is the world's 23rd-most-valuable brand. That kind of global recognition, built over decades, hasn't helped investors at all. The leading sportswear enterprise has faltered. And management has been in the middle of a turnaround that's taking longer than anticipated.

This consumer discretionary stock is down an alarming 80% from its peak (as of Oct. 12), set almost five years ago in November 2021. For investors, here's the only number that matters to the Nike story right now.

Image source: The Motley Fool.

Watch the top line
Investors don't have to look hard to find the prevailing metric that makes or breaks the turnaround. It all comes down to Nike's revenue.

In the latest fiscal quarter (Q1 2027 ended Aug. 31), the top line fell 4% year over year to $11.2 billion. This figure missed Wall Street analyst estimates. On a trailing 12-month basis, sales steadily declined over the past two and a half years.

Revenue is a clear signal of the company's demand trajectory. And it hasn't been encouraging. In North America, which is Nike's largest territory, sales climbed 2% in the first quarter.

Greater China has been wildly disappointing. Revenue there dipped 22% in the last fiscal quarter. "We continue to execute a marketplace reset in China," CEO Elliott Hill said on the earnings call.

Looking at the product picture, it's a mixed bag. On the one hand, performance sales were up high single digits. Running was up double digits. But sportswear revenue, defined by footwear such as the Air Force 1, Nike Dunk, and Air Max series, fell by low double digits. And the Jordan brand dropped by a mid-teens percentage.

Nike is desperately trying to drum up customer excitement. However, it will be a difficult road ahead. The leadership team expects revenue to decline by high single digits in fiscal 2027. Unless Nike returns to healthy and consistent sales growth, the rest of the income statement will feel the pain, particularly around profitability. From a historical perspective, margins will remain under pressure.

Management will hold an investor day next month. The business will reveal fresh long-term financial guidance that could add to the bearish sentiment if the outlook misses the mark.

Premium Feature

Moneyball Superscore

54/100

Today's Change

(

-0.06

%) $

-0.02

Current Price

$

35.33

A risky opportunity
At $35.11 per share, Nike's stock is at a 13-year low. It seems that sentiment could not be any worse. Contrarian investors might find this to be a compelling opportunity. After all, if Nike reports upbeat financial results, its shares could perform well.

I view the company as a risky bet, though. It's extremely difficult to invest in turnaround situations. There is so much uncertainty not only around actual progress being made, but also the timing of these possible improvements. I think investors are better off being overly cautious with Nike right now.